方法：将2008-07/2012-07入住我院的100例118眼中心性浆液性脉络膜视网膜病变患者按照抽签法随机地均分为对照组与观察组。对照组仅给予高压氧进行治疗，观察组在此基础上联合卵磷脂络合碘进行治疗。比较两组临床治疗效果、治疗后不同时间临床愈合情况、治疗前后视力、复发率以及不良反应发生情况。

结果：(1)对照组总眼数60眼，治疗有效眼数43眼，总有效率为71.7%； 观察组总眼数58眼，治疗有效眼数51眼，总有效率为87.9%，两组临床疗效相比具有统计学差异(P<0.05)；(2)两组治疗后2，4wk及3mo恢复正常眼数相比，差异均具有统计学意义(P<0.05，P<0.01)；(3)两组治疗前后视力差异均具有统计学意义(P<0.05，P<0.01)，且观察组治疗后视力明显优于对照组治疗后视力(P<0.05)；(4)经1a的随访，对照组复发眼数为6眼，复发率为10.0%； 观察组复发率为0眼，两组差异具有极显著的统计学意义(P<0.01)；(5)两组治疗过程中不良反应发生率无统计学差异(P>0.05)。

结论：高压氧联合卵磷脂络合碘治疗中心性浆液性脉络膜视网膜病变的疗效显著，安全性高，值得在临床治疗中心性浆液性脉络膜视网膜病变中加以推广并应用。

METHODS: Totally, 100 cases(118 eyes)of central serous chorioretinopathy hospitalized in our hospital from July 2008 to July 2012 were divided into control group and observation group according to random lot method. The control group only received hyperbaric oxygen treatment, and the observation group was given joint treatment with hyperbaric oxygen and iodized lecithin. The clinical outcome, healing condition at different times after treatment, visual acuity before and after treatment, the recurrence rate and adverse reaction were compared.

RESULTS:(1)The control group consisted of 60 eyes and 43 eyes showed therapeutic efficacy, and the total effective rate was 71.7%; the observation group consisted of 58 eyes and 51 eyes showed therapeutic efficacy, and the total effective rate was 87.9%, and there was a statistical difference between the two groups(P<0.05);(2)There was a statistical difference in number of recovered eyes 2, 4 weeks and 3 months after treatment(P<0.05, P<0.01);(3)There was a statistical difference in visual acuity comparison between the two groups before and after treatment(P<0.05, P<0.01), and visual acuity after treatment in the observation group was significantly better than that in the control group(P<0.05);(4)After 1-year follow-up, in the control group, the number of eyes with recurrence was 6, and the recurrence rate was 10.0%; in the observation group, the recurrence rate was 0, and the difference was of great statistical significance(P<0.01).(5)There was no significant difference in adverse reaction during the treatment(P> 0.05).

CONCLUSION:Hyperbaric oxygen therapy combined with jolethin in treating central serous chorioretinopathy shows significant effect and high safety. It is worth to be promoted and applied in the clinical treatment of central serous chorioretinopathyd.